Zurück zur Übersicht
| Frontiers in immunology. 2018 Dec 12. doi: 10.3389/fimmu.2018.02912. pmc: PMC6299915 |
| Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working Group. |
| Bomken S1, van der Werff Ten Bosch J2, Attarbaschi A3, Bacon CM4, Borkhardt A5, Boztug K6, Fischer U7, Hauck F8, Kuiper RP9, Lammens T10, Loeffen J11, Neven B12, Pan-Hammarström Q13, Quinti I14, Seidel MG15, Warnatz K16, Wehr C17, Lankester AC18, Gennery AR19 |
 Author information
|
|
Abstract Patients with inborn errors of immunity or DNA repair defects are at significant risk of developing malignancy and this complication of their underlying condition represents a substantial cause of morbidity and mortality. Whilst this risk is increasingly well-recognized, our understanding of the causative mechanisms remains incomplete. Diagnosing cancer is challenging in the presence of underlying co-morbidities and frequently other inflammatory and lymphoproliferative processes. We lack a structured approach to management despite recognizing the competing challenges of poor response to therapy and increased risk of toxicity. Finally, clinicians need guidance on how to screen for malignancy in many of these predisposing immunodeficiencies. In order to begin to address these challenges, we brought together representatives of European Immunology and Pediatric Haemato-Oncology to define the current state of our knowledge and identify priorities for clinical and research development. We propose key developmental priorities which our two communities will need to work together to address, collaborating with colleagues around the world. |
|
KEYWORDS: DNA repair defect, EBV (Epstein-Barr virus), cancer, chemotherapy, haematopoietic stem cell transplant, inborn error of immunity, lymphoma, screening |
|
Publikations ID: 30619276 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
